Activ8rlives’ Health and Wellness App Now Available on NHS Choice Health App Library

HUNTINGDON, U.K. - July 21, 2015 - PRLog -- Activ8rlives’ 3.0 Health and Wellness Monitor and Food Diary App (http://apps.nhs.uk/app/activ8rlives-3-0-health-and-wellness-monitor-and-food-diary/) is now available on the NHS Choices Health Apps Library (http://apps.nhs.uk/), having been reviewed and passed for inclusion by the clinical assurance team, which is made up of doctors, nurses and safety specialists.

The aim of the NHS Choices Health App Library (http://apps.nhs.uk/about/) is to provide a list of reviewed Apps that are safe to use, making it easier to find Apps that consumers can trust, improving patient and professional confidence, and enabling healthcare workers to be able to prescribe and recommend them to their patients.

In the latest version of the NHS Choices Health App Library, the new Health Apps Library Review Process (http://apps.nhs.uk/review-process/) ensures that Apps are relevant to people living in England, contains information from a verifiable or trusted source, comply with the Data Protection Act, ensure that they hold and use personal information appropriately, and above all make sure they are clinically safe and will not bring harm to the user. The National Information Board (https://www.gov.uk/government/organisations/national-info...) (NIB) aim to set regulation, accreditation and kite marking of technology and data enabled services later this year.

Inclusion of the Activ8rlives App in NHS Choices is a key step in giving healthcare professionals the confidence to recommend and prescribe Apps for use by their patients and is an important milestone for the Company as it develops integrated medical solutions for self-management of long-term conditions.

- Ends –

Caption: Activ8rlives 3.0 Health and Wellness Monitor and Food Diary App passed the Health Apps Library Review Process to be listed under Manage your Health on the NHS Choices Health App Library.

About Aseptika Limited (Activ8rlives):

Aseptika Limited is a healthcare company developing and marketing an integrated suite of self-monitoring devices and services under the Activ8rlives brand. We are developing integrated systems which can be used by consumers and their healthcare service providers to better self-manage (http://www.activ8rlives.com/solutions/self-monitoring-and...) long-term health conditions (LTHC) through self-monitoring.

The Company’s goal is to provide everyone with tools (and the understanding of how to apply them) so that most of us can keep healthy and well for most of the time. Self-management through self-monitoring is the motivation driving what we do.

Activ8rlives is unusual in that we are device agnostic, incorporating sensors and monitors ranging from consumer accessories to in vitro diagnostics (IVDs) with a focus on respiratory disease. All data is held together and can be cross analysed in the Cloud to provide forecasts and learning for the user and clinician.

The Company gained a patent in 2013 protecting the invention of a test for biomarkers (http://www.activ8rlives.com/about/news-and-events/news/2013/10/07/aseptika-awarded-uk-patent-for-home-test-for-lung-infections/) of Pseudomonas aeruginosa (PA) in the sputum of patients, which can be used to detect the on-set of an exacerbation and profile the efficacy of antibiotic treatment for each patient.

Aseptika won first place in a competition earlier in 2014 to reward the most “Promising eHealth EU SME”eHealth solution 2014 (http://www.activ8rlives.com/about/news-and-events/news/2014/04/03/aseptika-wins-first-place-for-most-promising-ehealth-solution-competition-2014/#sthash.jm6jQb3Q.dpuf)developed by an early-stage European SME. The 2014 Competition was organized by TICBioMed and had the endorsement of the Health and Wellbeing Unit of DG CONNECT of the European Commission. The judges commended Aseptika for the integrated approach it was taking in the support of patients with long-term respiratory disease (http://www.activ8rlives.com/solutions/clinical-trials/), providing the platform to self-manage their illness through self-monitoring. Central to the Company’s “hospital-at-home” concept, is a test in which the patient measures the level of virulence of the bacteria living in their lungs which from time to time, flare into a full and repeated chest infections.

Aseptika was a shortlisted finalist for the Cambridge News Top Innovations 2014 (http://www.cambridge-news.co.uk/Innovations-2014/story-22802672-detail/story.html) and won the  AXA PPP Health Tech & You (http://tr.axa-ppp.co.uk/do?B1D6C55B52E4CA5F29BAC297AFEC96616BEED2ADFC11507352CB0B093683219668A1A1FDC5BE1F9AAFCFBA515D62693465C0057B22D451DBCA5F71EBBA9990A9) Awards. Winner of the Discovery Start-up 2014 Competition (http://www.cambridgewireless.co.uk/news/article/default.aspx?objid=47697) run by Cambridge Wireless and Winner of the Hunts Post Huntingdonshire Business Innovation Awards 2014 (http://www.huntsbusinessawards.co.uk/). Named on Global Digital Health 100 Award (http://www.thejournalofmhealth.com/#!The-Journal-of-mHealth-Announces-the-2014-Global-Digital-Health-100-Recognising-the-Most-Innovative-Digital-Companies-in-Healthcare/cuhk/8C07B55F-084F-4C3E-BD3D-4A63343372FA) list, reflecting the importance of mobile and digital solutions.

Wearable Technology Awards 2015 (http://www.wearabletechnologyshow.net/awards) shortlisted Aseptika in three categories: Best Medical Device (placed third), Best Innovation and Overall Wearable Winner.

Aseptika was granted a patent in the United States and New Zealand protecting its invention for a test for respiratory infections early in 2015.

Aseptika has been short-listed as one of twenty semi-finalists for the Cisco British Innovation Gateway (BIG) Awards (http://www.thebigawards.co.uk/).

For more information on Aseptika Ltd, Activ8rlives and products, please visit: www.Activ8rlives.com

Activ8rlives, Activ8rlives.com, BuddyWOTCH and EyKos are trademarks of Aseptika Ltd.

For press information, please contact:

Jessica Auton, Marketing Director

jessica.auton@aseptika.com

Direct +44 (0)1480 352 821

Mobile +44 (0)7455 922 122